ONCY Oncolytics Biotech Inc.
Listings ·
Nasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial.
Oncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025.
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep is a proprietary isolate of reovirus that selectively replicates in RAS-mutated tumors and is described as activating innate and adaptive immune responses. The company says it is positioning pelareorep as a platform immunotherapy for gastrointestinal cancers, with the aim of advancing its GI programs to registration-enabled clinical studies. Combinations under study include chemotherapies, checkpoint inhibitors, CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. The company names metastatic colorectal cancer, second-line or later anal cancer, and metastatic pancreatic cancer as areas it is exploring for registrational programs. More than 1,600 patients have received at least one dose of study treatment with pelareorep in clinical studies. The company expects to pursue strategic alliances with larger companies for later development. The filing also states that there is substantial doubt about the company's ability to continue as a going concern.
| Product or program | What it is | Stage |
|---|---|---|
| Pelareorep | Intravenous reovirus isolate for RAS-mutated and GI tumors | clinical-stage |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $13.3 million | $15.4 million |
| Net income (loss) | -$28.8 million | -$22.8 million |
| Cash from operations | -$20.1 million | -$19.9 million |
| Cash and equivalents | $5.2 million | $11.1 million |
Opinion Negative view
Cash of $4.1 million covers about two months at average burn, and the company's own going concern language points the same way.
Our latest story on this, dated Jul 24, 2026: "Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 24, 2026: "Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027". The story links the filing or release it is based on. Read the story.
Oncolytics Biotech Inc. trades under the ticker ONCY on NASDAQ.
Oncolytics Biotech Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Oncolytics Biotech Inc. is 1129928. Its filings are on SEC EDGAR.
127,510,505 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Oncolytics Biotech Inc. under United States.
Our directory classifies Oncolytics Biotech Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Oncolytics Biotech Inc. is US68237V1035.
aibio.space lists Oncolytics Biotech Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep is a proprietary isolate of reovirus that selectively replicates in RAS-mutated tumors and is described as activating innate and adaptive immune responses.
Pelareorep: Intravenous reovirus isolate for RAS-mutated and GI tumors Stage: clinical-stage.
Oncolytics Biotech Inc. reported a net loss of $28.8 million for the fiscal year ended Dec 31, 2025, and used $20.1 million of cash in operations, per its annual report to the SEC.
$13.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 6-K. Source
Filed documents for a merger or acquisition. SEC Form F-4. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio